Craniofacial Defects
Conditions
Keywords
Craniofacial Defects, Implants
Brief summary
The goal of this retrospective study is to evaluate the clinical characteristics, efficiency, safety, and long-term performance of craniomaxillofacial (CMF) Porous Titanium Implants within the standard of care across children (0 - \<12 years old), adolescent (12 - \<22 years old), and adult (≥ 22 years old) populations.
Detailed description
The loss of bone substance or continuity in the cranial and/or facial region can result from trauma, infection, benign or malign tumor resection, and therapeutic side effects (e.g., radiotherapy). CMF Porous Titanium Implants are patient-specific solutions matched with the patient's anatomy to reconstruct bone defects accurately. Following a premarket clinical evaluation and considering long-term risk management, the decision to conduct a retrospective post-market clinical follow-up study was based on identifying possible residual risks and uncertainty about long-term safety and clinical performance that may impact the benefit/risk ratio of the CMF porous titanium devices, thereby ensuring the continued safety and efficacy of these CMF devices.
Interventions
DEVICECraniomaxillofacial (CMF) porous titanium implant
All patients were treated, between 2016 and 2023, with patient-specific CMF Porous Titanium Implants for facial and/or cranial reconstruction or restoration of bone defects.
Sponsors
Materialise
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Healthy volunteers
No
Inclusion criteria
* Age: Patients of any age are eligible for this study. * Patients treated with Materialise patient-specific CMF Porous Titanium Implants for facial and/or cranial reconstruction. * Patients who have followed Standard of Care, as determined in each case by the treating surgeon.
Exclusion criteria
* Known hypersensitivity to Titanium at the time of surgery. * Patients who had or will receive the TMJ Total Arthroplasty System. * Pregnancy at the time of surgery.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Last visit success rate of the device after the surgical implantation of Materialise patient-specific CMF Porous Titanium Implants | Last visit (up to 8 years post-implantation) | Success is defined as follows: \- The device is securely in place and functional as of the last follow-up or until its removal for reasons unrelated to the device itself. Failure is defined as follows: * Reoperation without device removal related to the device. * Reoperation with device removal related to the device. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| General post-operative complications up to standard of care (SOC) follow-up | 4 weeks, 3 months, 1 year, 2-3 years, up to 8 years follow-up | Complications related and unrelated to CMF Porous Titanium Implants, including infection, pain, implant migration, implant exposure, failure of implant, device subsidence, device fracture, diplopia, hematoma, dysesthesia, osteolysis, fistula, wound dehiscence, delayed healing, or others. |
| Re-intervention rate, implant-related or not | Up to 8 years follow-up | — |
| Intraoperative blood loss (mL) | At procedure | Estimated blood loss by visual inspection or gravimetric method |
| Technical success of the implantation | At procedure | Defined by the surgeon, including but not limited to the implantation of the CMF Porous Titanium Implant and guides (if applicable) according to the pre-operative plan without technical difficulties, including design issues, placement issues, planning issues, guides, or others. |
| Perioperative complications related and unrelated to CMF Porous Titanium Implants | Up to the moment the patient is discharged from the hospital after the procedure (discharge), up to several weeks, depending on defect severity and recovery progress | Complications related and unrelated to CMF Porous Titanium Implants, including allergic reaction to the anesthetic or titanium (anaphylaxis), complications related to the anesthesia, hematoma, or others. |
| Implant migration | 3 months, 1 year follow-up | Migration will be quantified by calculating the difference between the immediate post-operative and 3-month and 1-year post-operative scans. |
| Implant time of the device | From surgery up to 8 years | — |
| Surgical operation time | At procedure | — |
| Total hospital post-operative stay | Up to the moment the patient is discharged from the hospital after the procedure (discharge), up to several weeks, depending on defect severity and recovery progress | Time of discharge will be registered in eCRF. Post-operative treatment carried out according to the standard practice of the investigational sites will be registered in the eCRF. |
| Accuracy of the device implantation compared to the pre-operative plan | 4 weeks follow-up | Accuracy will be quantified by superpositioning the post-operative images with the planning. |
Countries
Denmark, France
Contacts
Primary ContactDorien Haesen, PhD
Outcome results
None listed